CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells

Open Biology

Volumn 6, Issue 6, 2016, Pages

  Gao, Darrin ^a,c   Rahbar, Ramtin ^b   Fish, Eleanor N ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anabolic metabolism; Breast cancer; CCL5; CCR5; Glycolysis

Indexed keywords

CCL5 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; GLUCOSE TRANSPORTER 1; RANTES; SLC2A1 PROTEIN, HUMAN;

ANIMAL; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; FEMALE; GLYCOLYSIS; HUMAN; MCF-7 CELL LINE; METABOLISM; METABOLOMICS; MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL5; FEMALE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; MCF-7 CELLS; METABOLOMICS; MICE; RECEPTORS, CCR5;

EID: 84978194819     PISSN: None     EISSN: 20462441     Source Type: Journal    
DOI: 10.1098/rsob.160122     Document Type: Article

References (30)

1. Vendramini-Costa DB, Carvalho JE. 2012 Molecular link mechanisms between inflammation and cancer. Curr. Pharm. Des. 18, 3831-3852. (doi:10.2174/ 138161212802083707)
2. Mantovani A, Allavena P, Sica A, Balkwill F. 2008 Cancer-related inflammation. Nature 454, 436-444. (doi:10.1038/nature07205)
3. Jiang X, Shapiro DJ. 2014 The immune system and inflammation in breast cancer. Mol. Cell Endocrinol. 382, 673- 682. (doi:10.1016/j.mce. 2013.06.003)
4. De la Cruz-Merino L et al. 2013 New insights into the role of the immune microenvironment in breast carcinoma. Clin. Dev. Immunol. 2013, 785317. (doi:10.1155/2013/785317)
5. Martinez-Outschoorn U, Sotgia F, Lisanti MP. 2014 Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol. 41, 195-216. (doi:10.1053/j.seminoncol.2014.03.002)
6. Griffith JW, Sokol CL, Luster AD. 2014 Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659-702. (doi:10.1146/annurev-immunol-032713-120145)
7. Muller A et al. 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56. (doi:10.1038/35065016)
8. See AL, Chong PK, Lu SY, Lim YP. 2014 CXCL3 is a potential target for breast cancer metastasis. Curr. Cancer Drug Targets 14, 294- 309. (doi:10.2174/ 1568009614666140305222328)
9. Biswas S et al. 2014 CXCL13- CXCR5 co-expression regulates epithelial to mesenchyal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res. Treat 143, 265-276. (doi:10. 1007/s10549-013-2811-8)
10. Luboshits G et al. 1999 Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59, 4681- 4687.
11. Zhang Y, Lv D, Kim H-J, Kurt RA, Bu W, Li Y, Ma X. 2013 A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloidderived suppressor cells. Cell Res. 23, 394-408. (doi:10.1038/cr.2012.178)
12. Marques RE, Guabiraba R, Russo RC, Teixeira MM. 2013 Targeting CCL5 in inflammation. Expert Opin. Ther. Targets 17, 1439-1460. (doi:10.1517/ 14728222.2013.837886)
13. Murooka TT, Rahbar R, Fish EN. 2009 CCL5 promotes proliferation of MCF-7 cells through mTORdependent mRNA translation. Biochem. Biophys. Res. Commun. 387, 381-386. (doi:10.1016/j.bbrc. 2009.07.035)
14. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A. 2009 The chemokine CCL5 as a prognostic factor predicting disease progression in stage II breast cancer patients. Clin. Cancer Res. 12, 4474-4480. (doi:10.1158/1078-0432.CCR-06-0074)
15. Warburg O. 1956 On the origin of cancer cells. Science 123, 309- 314. (doi:10.1126/science.123. 3191.309)
16. Boroughs LK, DeBerardinis RJ. 2015 Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351-359. (doi:10.1038/ ncb3124)
17. Szablewski L. 2013 Expression of glucose transporters in cancers. Biochim. Biophys. Acta 1835, 164-169. (doi:10.1016/j.bbcan.2012.12.004)
18. Chan O, Burke JD, Gao DF, Fish EN. 2012 The chemokine CCL5 regulates glucose uptake and AMP kinase signaling in activated T cells to facilitate chemotaxis. J. Biol. Chem. 287, 29 406-29 416. (doi:10.1074/jbc.M112.348946)
19. Zhao FQ. 2014 Biology of glucose transport in the mammary gland. J. Mammary Gland Biol. Neopasia 19, 3-17. (doi:10.1007/s10911-013-9310-8)
20. Kocdor MA, Kocdor H, Pereira JS, Vanegas JE, Russo IH, Russo J. 2013 Progressive increase of glucose transport-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis. Clin. Transl. Oncol. 15, 55-64. (doi:10.1007/s12094-012-0882-3)
21. Fang J, Zhou SH, Fan J, Yan SX. 2015 Roles of glucose transporter-1 and the phosphatidylinositol 3-kinase/protein kinase B pathways in cancer radioresistance. Mol. Med. Rep. 11, 1573-1581.
22. Pico-Ruez M et al. 2016 Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/Sox2/miR-302bmediated malignant progression. Cancer Res. 76, 491- 504. (doi:10.1158/0008-5472.CAN-15-0927)
23. D'Esposito V et al. 2012 Adipocyte-released insulinlike growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55, 2811-2822. (doi:10.1007/ s00125-012-2629-7)
24. Shimobayashi M, Hall MN. 2014 Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 15, 1320-1323. (doi:10.1038/nrm3757)
25. Buller CL, Loberg RD, Fan M-H, Zhu Q, Park JL, Vesely E, Inoki K, Guan K-L, Brosius FC. 2008 A GSK/ TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am. J. Physiol. Cell Physiol. 295, C836- C843. (doi:10.1152/ajpcell.00554.2007)
26. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. 2003 Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell Biol. 23, 7315-7328. (doi:10.1128/MCB. 23.20.7315-7328.2003)
27. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. 2012 CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72, 3839- 3850. (doi:10.1158/ 0008-5472.CAN-11-3917)
28. Zhang Y, Meng FY, Li WL, Zhou CX, Guan Z, Fan H. 2013 Association of chemotactic factor receptor 5 gene with breast cancer. Genet. Mol. Res. 12, 5289-5300. (doi:10.4238/2013.November.7.4)
29. Boyle ST, Faulkner JW, McColl SR, Kochetkova M. 2015 The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumour-promoting macrophages. Mol. Cancer 14, 115- 129. (doi:10. 1186/s12943-015-0394-1)
30. Gattenby RA, Gillies RJ. 2004 Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899. (doi:10.1038/nrc1478)